(Q38062022)

28 August 2017

1 reference

title

Pathways and targets in hepatocellular carcinoma (English)

1 reference

28 August 2017

Amanda Psyrri

1

1 reference

28 August 2017

Nikolaos Arkadopoulos

2

1 reference

28 August 2017

Maria Vassilakopoulou

3

1 reference

28 August 2017

Vassilios Smyrniotis

4

1 reference

28 August 2017

George Dimitriadis

5

1 reference

28 August 2017

publication date

1 October 2012

1 reference

Expert Review of Anticancer Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

12

1 reference

28 August 2017

issue

10

1 reference

28 August 2017

page(s)

1347-1357

1 reference

28 August 2017

cites work

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Hepatocellular carcinoma: recent trends in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Epidemiology and prevention of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

A prospective study of obesity and cancer risk (Sweden).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Diagnosis and Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Randomized controlled trial of screening for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Screening for liver cancer: results of a randomised controlled trial in Qidong, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Translational strategies for cancer prevention in liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Pathogenesis of hepatocellular carcinoma and molecular therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Genetics of hepatocellular tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Increased MAPK expression and activity in primary human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

C-raf expression in early rat liver tumorigenesis after promotion with polychlorinated biphenyls or phenobarbital

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Angiogenesis in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phosphoinositide signalling in cancer: beyond PI3K and PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.113

21 January 2018

Identifiers

DOI

10.1586/ERA.12.113

1 reference

28 August 2017

1 reference